Emergency in the United States. The country is by far the most bereaved in the world by the Covid-19 epidemic and the number of new daily cases there is exploding to now exceed 12 million patients, according to Johns Hopkins University. To deal with this situation, theThe American Medicines Agency (FDA) granted on Saturday, November 21, an authorization for a treatment with synthetic antibodies from the company Regeneron.
This change comes after administration of REGEN-COV2, a combination of two laboratory-made antibodies, has been shown to reduce Covid-19-related hospitalizations or emergency room visits in patients with secondary illnesses or ” comorbidities “. This treatment had notably helped treat Donald Trump when he was struck by the virus in early October.
Allowing these monoclonal antibody therapies could allow patients to avoid hospitalization and ease the burden on our healthcare system.Stephen Hahn, Head of the FDA
Regeneron chairman Leonard Schleifer assured that the move constituted “an important step in the fight against Covid-19, because high-risk patients in the United States will have access to a promising therapy at the start of their infection”. These antibodies mimic what the immune system does after infection with the coronavirus, by going to block the tip of the virus that allows it to attach to and penetrate human cells.
This treatment is considered to be more effective during the initial phase of the infection, when the antibodies still have a chance to control the invader, and not during the second phase of Covid-19, when the danger is no longer the virus. itself, but the overreaction of the immune system which attacks the lungs and other organs.
It is the second synthetic antibody treatment to receive “Emergency Use Clearance” (EUA) from the FDA. A similar therapy developed by the American company Eli Lilly had already obtained this status on November 9. Regeneron has received more than $ 450 million from the US government for its efforts to develop drugs against Covid-19.